TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

The genetic testing results also inform patients’ family members about their cancer risks so they can be proactive in screening and prevention. For now, GENETECA™ is only available to people with ...

Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic genomic test and/or made comparisons between those tests, reported ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...